Steven Leibowitz, MD
Ophthalmology · Las Vegas, NVNPI 1679631014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $104,511 of the $147,378 with a category attached, or 70.9%. Amgen accounts for 99.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $75,268 and has fallen 83.6% since, to $12,320 in 2025. Among ophthalmology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $421.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$146K
- Biotissue Holdings Inc.$216
- Bausch & Lomb Americas Inc.$168
- Averitas Pharma Inc.$119
- Galderma Laboratories, L.p.$108
- Argenx US, Inc.$99
- plus $323 from 9 others
Across 61 payments — averaging $158.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$10K
What the payments were for
- Consulting fees$10,0707%
- Speaking & faculty fees$104,51171%
- Travel & lodging$22,07215%
- Food & beverage$10,7077%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 329 | $146,347 |
| Biotissue Holdings Inc. | 2 | $216 |
| Bausch & Lomb Americas Inc. | 4 | $168 |
| Averitas Pharma Inc. | 1 | $119 |
| Galderma Laboratories, L.p. | 1 | $108 |
| Argenx US, Inc. | 1 | $99 |
| Recordati_rare_diseases_inc. | 1 | $88 |
| Sun Pharmaceutical Industries Inc. | 2 | $71 |
| Shire North American Group Inc | 3 | $41 |
| Dompe US, Inc. | 1 | $34 |
| Axogen | 1 | $20 |
| Novartis | 1 | $18 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$147,378 in reported general payments places this provider in the 95th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 25 | $29,000 |
| RestasisCyclosporine | 21 | $26,120 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 199 | $9,182 |
| ErythromycinErythromycin Base | 210 | $1,926 |
| Latanoprost | 62 | $1,230 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $411 |
| Timolol Maleate | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $168 | $29,00025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
- Surjeet SinghLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.